[
    {
        "text": "thank you for the kind introduction and",
        "start": 0.11,
        "duration": 3.4
    },
    {
        "text": "thank you again to the organizing",
        "start": 2.49,
        "duration": 2.789
    },
    {
        "text": "committee for the for the honor to be",
        "start": 3.51,
        "duration": 3.869
    },
    {
        "text": "here today so I'm going to talk today",
        "start": 5.279,
        "duration": 3.331
    },
    {
        "text": "about seeing a small molecule drug",
        "start": 7.379,
        "duration": 3.781
    },
    {
        "text": "discovery and just a brief way of my",
        "start": 8.61,
        "duration": 4.35
    },
    {
        "text": "background I was going to show a map but",
        "start": 11.16,
        "duration": 3.149
    },
    {
        "text": "unlike many of my colleagues I'd be a",
        "start": 12.96,
        "duration": 2.58
    },
    {
        "text": "bit embarrassed that it would just be",
        "start": 14.309,
        "duration": 4.14
    },
    {
        "text": "California so I haven't had a lot of",
        "start": 15.54,
        "duration": 5.63
    },
    {
        "text": "global travels quite yet but that's ok",
        "start": 18.449,
        "duration": 5.101
    },
    {
        "text": "so my undergraduate career obtained my",
        "start": 21.17,
        "duration": 4.99
    },
    {
        "text": "bachelor's University laverne's a small",
        "start": 23.55,
        "duration": 4.489
    },
    {
        "text": "private Institute in Southern California",
        "start": 26.16,
        "duration": 4.05
    },
    {
        "text": "I'm actually went there to play",
        "start": 28.039,
        "duration": 5.741
    },
    {
        "text": "basketball and did a summary research",
        "start": 30.21,
        "duration": 5.88
    },
    {
        "text": "internship at cornell i was there i took",
        "start": 33.78,
        "duration": 4.529
    },
    {
        "text": "my MCATs as a pre-med major unlike i",
        "start": 36.09,
        "duration": 3.66
    },
    {
        "text": "think many pre-meds though when i took",
        "start": 38.309,
        "duration": 3.09
    },
    {
        "text": "organic synthetic chemistry i fell in",
        "start": 39.75,
        "duration": 4.89
    },
    {
        "text": "love with it and then furthermore an",
        "start": 41.399,
        "duration": 4.741
    },
    {
        "text": "advisor of mine introduced me to",
        "start": 44.64,
        "duration": 3.149
    },
    {
        "text": "classics and total synthesis which was",
        "start": 46.14,
        "duration": 3.12
    },
    {
        "text": "written by Casey Nicholaw and Eric",
        "start": 47.789,
        "duration": 3.811
    },
    {
        "text": "Sorensen in the late 90s and I was just",
        "start": 49.26,
        "duration": 4.47
    },
    {
        "text": "fascinated by the ability to construct",
        "start": 51.6,
        "duration": 4.619
    },
    {
        "text": "large complex natural products in a",
        "start": 53.73,
        "duration": 4.829
    },
    {
        "text": "laboratory setting with your hands using",
        "start": 56.219,
        "duration": 3.691
    },
    {
        "text": "small commercial available building",
        "start": 58.559,
        "duration": 2.761
    },
    {
        "text": "blocks and so that's what really drove",
        "start": 59.91,
        "duration": 4.859
    },
    {
        "text": "my decision to then do my PhD in Casey's",
        "start": 61.32,
        "duration": 6.99
    },
    {
        "text": "lab at UCSD and s scripts and I was",
        "start": 64.769,
        "duration": 5.64
    },
    {
        "text": "exposed not only to total synthesis but",
        "start": 68.31,
        "duration": 4.65
    },
    {
        "text": "also synthetic methodology so you can",
        "start": 70.409,
        "duration": 4.771
    },
    {
        "text": "see some of those highlighted here the",
        "start": 72.96,
        "duration": 3.33
    },
    {
        "text": "method all ages and left in the middle",
        "start": 75.18,
        "duration": 3.06
    },
    {
        "text": "and the right thigh Upton and I have to",
        "start": 76.29,
        "duration": 4.38
    },
    {
        "text": "thank a couple grad students Brian Sofia",
        "start": 78.24,
        "duration": 4.44
    },
    {
        "text": "and Mark Zack who also really led the",
        "start": 80.67,
        "duration": 4.47
    },
    {
        "text": "charge on thigh Upton that we",
        "start": 82.68,
        "duration": 5.369
    },
    {
        "text": "synthesized in 2004 so I saw this is",
        "start": 85.14,
        "duration": 4.08
    },
    {
        "text": "really a great training ground for",
        "start": 88.049,
        "duration": 2.941
    },
    {
        "text": "biotech and pharma industry good",
        "start": 89.22,
        "duration": 3.539
    },
    {
        "text": "exposure to a broad range of synthetic",
        "start": 90.99,
        "duration": 3.989
    },
    {
        "text": "organic chemistry reactions and so I",
        "start": 92.759,
        "duration": 4.261
    },
    {
        "text": "joined Genentech in 2008 in their",
        "start": 94.979,
        "duration": 4.921
    },
    {
        "text": "discovery chemistry group I worked on an",
        "start": 97.02,
        "duration": 5.099
    },
    {
        "text": "oncology program to start mtor kinase we",
        "start": 99.9,
        "duration": 3.69
    },
    {
        "text": "advanced molecule into the clinic and",
        "start": 102.119,
        "duration": 3.661
    },
    {
        "text": "then was fortuitous label to join as",
        "start": 103.59,
        "duration": 4.08
    },
    {
        "text": "cameras to team leader the lirc to",
        "start": 105.78,
        "duration": 4.049
    },
    {
        "text": "program shortly thereafter and that was",
        "start": 107.67,
        "duration": 4.92
    },
    {
        "text": "really my first taste of neuroscience",
        "start": 109.829,
        "duration": 4.891
    },
    {
        "text": "and cns small molecule drug discovery",
        "start": 112.59,
        "duration": 4.41
    },
    {
        "text": "and drew me in so I mean to talking",
        "start": 114.72,
        "duration": 4.469
    },
    {
        "text": "about lurk in just a minute but I then",
        "start": 117.0,
        "duration": 3.689
    },
    {
        "text": "went on to work on dl k another",
        "start": 119.189,
        "duration": 2.941
    },
    {
        "text": "neuroscience target that we have a",
        "start": 120.689,
        "duration": 3.03
    },
    {
        "text": "molecule in a clinic or Genentech i",
        "start": 122.13,
        "duration": 2.849
    },
    {
        "text": "should say has a molecule on the clinic",
        "start": 123.719,
        "duration": 5.191
    },
    {
        "text": "and ALS and phase one and then about a",
        "start": 124.979,
        "duration": 7.401
    },
    {
        "text": "year ago was had the opportunity to join",
        "start": 128.91,
        "duration": 5.84
    },
    {
        "text": "honey that launched in May of last year",
        "start": 132.38,
        "duration": 4.08
    },
    {
        "text": "called Denali therapeutics and I'm",
        "start": 134.75,
        "duration": 2.58
    },
    {
        "text": "currently heading up the middle",
        "start": 136.46,
        "duration": 5.48
    },
    {
        "text": "medicinal chemistry group at Sonali so",
        "start": 137.33,
        "duration": 7.5
    },
    {
        "text": "Raina did an amazing job already",
        "start": 141.94,
        "duration": 4.93
    },
    {
        "text": "presenting Alzheimer's disease for me so",
        "start": 144.83,
        "duration": 3.18
    },
    {
        "text": "I don't have to talk too much about this",
        "start": 146.87,
        "duration": 4.17
    },
    {
        "text": "slide but really what draws my",
        "start": 148.01,
        "duration": 5.16
    },
    {
        "text": "inspiration and Denalis inspiration in",
        "start": 151.04,
        "duration": 4.02
    },
    {
        "text": "this field focused on neuro degeneration",
        "start": 153.17,
        "duration": 3.99
    },
    {
        "text": "is the unmet medical needs as was",
        "start": 155.06,
        "duration": 3.8
    },
    {
        "text": "mentioned by the previous speaker and so",
        "start": 157.16,
        "duration": 3.99
    },
    {
        "text": "Alzheimer's and Parkinson's are the two",
        "start": 158.86,
        "duration": 3.49
    },
    {
        "text": "that you hear most commonly about",
        "start": 161.15,
        "duration": 4.02
    },
    {
        "text": "largely because of the sheer numbers i",
        "start": 162.35,
        "duration": 4.53
    },
    {
        "text": "were to she already talked about the the",
        "start": 165.17,
        "duration": 2.85
    },
    {
        "text": "numbers for Alzheimer's disease",
        "start": 166.88,
        "duration": 3.24
    },
    {
        "text": "Parkinson's disease is just behind in",
        "start": 168.02,
        "duration": 4.23
    },
    {
        "text": "terms of its prevalence and the number",
        "start": 170.12,
        "duration": 4.2
    },
    {
        "text": "of people that are that are impacted and",
        "start": 172.25,
        "duration": 4.68
    },
    {
        "text": "so this is not even to mention the",
        "start": 174.32,
        "duration": 4.8
    },
    {
        "text": "number of other different rare diseases",
        "start": 176.93,
        "duration": 4.95
    },
    {
        "text": "such as ALS FTD kraviz a disease gaze",
        "start": 179.12,
        "duration": 4.8
    },
    {
        "text": "disease Huntington's disease lysosomal",
        "start": 181.88,
        "duration": 3.51
    },
    {
        "text": "storage disorders and the list goes on",
        "start": 183.92,
        "duration": 3.66
    },
    {
        "text": "and none of these really have any cures",
        "start": 185.39,
        "duration": 4.08
    },
    {
        "text": "or effective treatments and symptomatic",
        "start": 187.58,
        "duration": 5.1
    },
    {
        "text": "treatments are moderate at best for some",
        "start": 189.47,
        "duration": 5.91
    },
    {
        "text": "of these diseases and so that's why",
        "start": 192.68,
        "duration": 3.93
    },
    {
        "text": "we're really committed to nerja",
        "start": 195.38,
        "duration": 5.4
    },
    {
        "text": "narration at sonali so to give a little",
        "start": 196.61,
        "duration": 6.81
    },
    {
        "text": "bit of a highlight then on leucine-rich",
        "start": 200.78,
        "duration": 4.65
    },
    {
        "text": "repeat kinase too when I was at",
        "start": 203.42,
        "duration": 3.6
    },
    {
        "text": "Genentech we started this program in",
        "start": 205.43,
        "duration": 4.62
    },
    {
        "text": "2009 shortly after the identification of",
        "start": 207.02,
        "duration": 6.27
    },
    {
        "text": "the gene I believe in 2004 the interest",
        "start": 210.05,
        "duration": 4.98
    },
    {
        "text": "from genentech as well as many others in",
        "start": 213.29,
        "duration": 3.75
    },
    {
        "text": "the industry is because of its genetic",
        "start": 215.03,
        "duration": 4.59
    },
    {
        "text": "link so it it's known mutations are",
        "start": 217.04,
        "duration": 3.87
    },
    {
        "text": "known as the one of the most common",
        "start": 219.62,
        "duration": 3.089
    },
    {
        "text": "causes of familial Parkinson's disease",
        "start": 220.91,
        "duration": 4.86
    },
    {
        "text": "along with mutations in GBA the most",
        "start": 222.709,
        "duration": 5.341
    },
    {
        "text": "common g20 19's actually increases this",
        "start": 225.77,
        "duration": 4.56
    },
    {
        "text": "kinase activity so it lent itself to a",
        "start": 228.05,
        "duration": 4.32
    },
    {
        "text": "hypothesis that if we could come up with",
        "start": 230.33,
        "duration": 4.5
    },
    {
        "text": "look to specific kinase inhibitors that",
        "start": 232.37,
        "duration": 5.64
    },
    {
        "text": "we would be able to ideally treat lurk",
        "start": 234.83,
        "duration": 4.8
    },
    {
        "text": "to patients carrying pathogenic",
        "start": 238.01,
        "duration": 4.14
    },
    {
        "text": "mutations and then because lurk to",
        "start": 239.63,
        "duration": 4.17
    },
    {
        "text": "zynga's indistinguishable or Luke to",
        "start": 242.15,
        "duration": 3.44
    },
    {
        "text": "related PD is indistinguishable from",
        "start": 243.8,
        "duration": 3.99
    },
    {
        "text": "idiopathic PD we're hopeful that this",
        "start": 245.59,
        "duration": 3.28
    },
    {
        "text": "would translate to a sporadic",
        "start": 247.79,
        "duration": 3.72
    },
    {
        "text": "parkinson's disease patient population",
        "start": 248.87,
        "duration": 4.65
    },
    {
        "text": "so that was the hypothesis that we had",
        "start": 251.51,
        "duration": 3.75
    },
    {
        "text": "at the time and why we started the",
        "start": 253.52,
        "duration": 4.83
    },
    {
        "text": "program at Genentech and so I'm going to",
        "start": 255.26,
        "duration": 4.62
    },
    {
        "text": "do the team especially the chemistry",
        "start": 258.35,
        "duration": 3.449
    },
    {
        "text": "team is significant injustice by showing",
        "start": 259.88,
        "duration": 3.99
    },
    {
        "text": "about a year's worth of work on one",
        "start": 261.799,
        "duration": 4.391
    },
    {
        "text": "slide but due to times sake",
        "start": 263.87,
        "duration": 5.14
    },
    {
        "text": "that's what I have to do so we were able",
        "start": 266.19,
        "duration": 4.29
    },
    {
        "text": "to start with a high-throughput",
        "start": 269.01,
        "duration": 3.47
    },
    {
        "text": "screening hit I was fairly efficient",
        "start": 270.48,
        "duration": 4.23
    },
    {
        "text": "usually then undergo hit to lead",
        "start": 272.48,
        "duration": 4.12
    },
    {
        "text": "optimization in an early drug discovery",
        "start": 274.71,
        "duration": 3.81
    },
    {
        "text": "setting so we're able to through",
        "start": 276.6,
        "duration": 4.29
    },
    {
        "text": "computational analyses master molecular",
        "start": 278.52,
        "duration": 4.83
    },
    {
        "text": "pair activity cliff analyses all of this",
        "start": 280.89,
        "duration": 4.38
    },
    {
        "text": "work is published in this publication in",
        "start": 283.35,
        "duration": 4.53
    },
    {
        "text": "2012 identified this methoxy group",
        "start": 285.27,
        "duration": 4.74
    },
    {
        "text": "selectivity handle which really brought",
        "start": 287.88,
        "duration": 4.95
    },
    {
        "text": "in a lot of luck to specificity so ji",
        "start": 290.01,
        "duration": 5.16
    },
    {
        "text": "7080 was a superior compound from our",
        "start": 292.83,
        "duration": 5.01
    },
    {
        "text": "from our initial hit and then carrying",
        "start": 295.17,
        "duration": 4.32
    },
    {
        "text": "out subsequent optimization we were able",
        "start": 297.84,
        "duration": 4.05
    },
    {
        "text": "to install a trifle or methyl group on",
        "start": 299.49,
        "duration": 4.23
    },
    {
        "text": "the perimeter ring and this did a number",
        "start": 301.89,
        "duration": 3.51
    },
    {
        "text": "of different favorable things for us it",
        "start": 303.72,
        "duration": 3.15
    },
    {
        "text": "brought in cell potency metabolic",
        "start": 305.4,
        "duration": 3.33
    },
    {
        "text": "stability and brain penetration all",
        "start": 306.87,
        "duration": 3.42
    },
    {
        "text": "things that you really have to walk a",
        "start": 308.73,
        "duration": 3.03
    },
    {
        "text": "tightrope and balance when you're",
        "start": 310.29,
        "duration": 4.74
    },
    {
        "text": "working in this space so then that",
        "start": 311.76,
        "duration": 5.78
    },
    {
        "text": "resulted in 10 23 which is a widely used",
        "start": 315.03,
        "duration": 4.62
    },
    {
        "text": "biological chemical probe in a number of",
        "start": 317.54,
        "duration": 4.17
    },
    {
        "text": "different labs a study lurk to function",
        "start": 319.65,
        "duration": 3.96
    },
    {
        "text": "unfortunately for a drug discovery",
        "start": 321.71,
        "duration": 3.31
    },
    {
        "text": "advancement the molecule is found to be",
        "start": 323.61,
        "duration": 3.87
    },
    {
        "text": "genotoxic and so we had to look for ways",
        "start": 325.02,
        "duration": 5.16
    },
    {
        "text": "of further improving this we're able to",
        "start": 327.48,
        "duration": 5.91
    },
    {
        "text": "dial out or rid of a few other off",
        "start": 330.18,
        "duration": 5.1
    },
    {
        "text": "target kindnesses of concern and we were",
        "start": 333.39,
        "duration": 4.65
    },
    {
        "text": "able to have a compound that was then",
        "start": 335.28,
        "duration": 5.58
    },
    {
        "text": "devoid of genotoxic issues in 7 9 15 and",
        "start": 338.04,
        "duration": 5.43
    },
    {
        "text": "this was really our first lead molecule",
        "start": 340.86,
        "duration": 4.26
    },
    {
        "text": "that satisfied all of our criteria that",
        "start": 343.47,
        "duration": 4.17
    },
    {
        "text": "we'd set forth and our target candidate",
        "start": 345.12,
        "duration": 3.66
    },
    {
        "text": "profile with good brain penetration",
        "start": 347.64,
        "duration": 3.57
    },
    {
        "text": "selectivity and potency and then",
        "start": 348.78,
        "duration": 4.32
    },
    {
        "text": "simultaneously we're able to address a",
        "start": 351.21,
        "duration": 4.32
    },
    {
        "text": "potential solubility issue of 7 9 15 and",
        "start": 353.1,
        "duration": 4.35
    },
    {
        "text": "bring in some structural differentiation",
        "start": 355.53,
        "duration": 5.04
    },
    {
        "text": "in the advancement 208 77 which was an",
        "start": 357.45,
        "duration": 4.59
    },
    {
        "text": "amino pure ozone molecule that showed a",
        "start": 360.57,
        "duration": 3.27
    },
    {
        "text": "lot of the desirable or favorable",
        "start": 362.04,
        "duration": 4.92
    },
    {
        "text": "attributes of 7 9 15 so all of this was",
        "start": 363.84,
        "duration": 5.04
    },
    {
        "text": "accomplished with a really great",
        "start": 366.96,
        "duration": 4.83
    },
    {
        "text": "chemistry team and project team through",
        "start": 368.88,
        "duration": 4.8
    },
    {
        "text": "property and structure-based drug design",
        "start": 371.79,
        "duration": 4.68
    },
    {
        "text": "we also work closely with our dmpk group",
        "start": 373.68,
        "duration": 4.65
    },
    {
        "text": "and jing wang lu specifically in",
        "start": 376.47,
        "duration": 4.5
    },
    {
        "text": "developing a rat cassette a blood brain",
        "start": 378.33,
        "duration": 4.29
    },
    {
        "text": "barrier screening model which reduced",
        "start": 380.97,
        "duration": 4.5
    },
    {
        "text": "animal usage and was able to allow us to",
        "start": 382.62,
        "duration": 5.46
    },
    {
        "text": "rapidly advanced the program we were",
        "start": 385.47,
        "duration": 4.71
    },
    {
        "text": "then able to take the two molecules on",
        "start": 388.08,
        "duration": 4.05
    },
    {
        "text": "the right and confirm in vivo target",
        "start": 390.18,
        "duration": 4.109
    },
    {
        "text": "engagements and show strong peak APD",
        "start": 392.13,
        "duration": 3.51
    },
    {
        "text": "relationships with lurk two biomarkers",
        "start": 394.289,
        "duration": 2.761
    },
    {
        "text": "and rode in",
        "start": 395.64,
        "duration": 4.05
    },
    {
        "text": "to non-human primates we saw significant",
        "start": 397.05,
        "duration": 5.609
    },
    {
        "text": "PD knock down at low doses in the brain",
        "start": 399.69,
        "duration": 5.46
    },
    {
        "text": "as well as in the periphery and where",
        "start": 402.659,
        "duration": 4.951
    },
    {
        "text": "this program stands as today there was",
        "start": 405.15,
        "duration": 4.71
    },
    {
        "text": "an effort that was undertaken a few",
        "start": 407.61,
        "duration": 3.63
    },
    {
        "text": "years ago which i think is pretty unique",
        "start": 409.86,
        "duration": 2.97
    },
    {
        "text": "and something that I hope they're to see",
        "start": 411.24,
        "duration": 3.54
    },
    {
        "text": "more of in this field as a",
        "start": 412.83,
        "duration": 3.78
    },
    {
        "text": "pre-competitive consortium with Michael",
        "start": 414.78,
        "duration": 3.479
    },
    {
        "text": "J Fox foundation so it was really great",
        "start": 416.61,
        "duration": 2.94
    },
    {
        "text": "to work with them over the past few",
        "start": 418.259,
        "duration": 3.63
    },
    {
        "text": "years and then other industry partners",
        "start": 419.55,
        "duration": 5.07
    },
    {
        "text": "Pfizer and Merck contributed",
        "start": 421.889,
        "duration": 4.77
    },
    {
        "text": "structurally distinct kinase inhibitors",
        "start": 424.62,
        "duration": 4.139
    },
    {
        "text": "to this effort as well and so right now",
        "start": 426.659,
        "duration": 3.931
    },
    {
        "text": "it's still undergoing efforts to really",
        "start": 428.759,
        "duration": 4.41
    },
    {
        "text": "study the and characterize the effects",
        "start": 430.59,
        "duration": 5.609
    },
    {
        "text": "of luck to inhibitors so with that then",
        "start": 433.169,
        "duration": 5.761
    },
    {
        "text": "a few slides then and taking a forward",
        "start": 436.199,
        "duration": 4.921
    },
    {
        "text": "look and speaking a little bit towards",
        "start": 438.93,
        "duration": 4.709
    },
    {
        "text": "Denali unfortunately I can't share",
        "start": 441.12,
        "duration": 4.259
    },
    {
        "text": "specific information quite yet although",
        "start": 443.639,
        "duration": 3.301
    },
    {
        "text": "hopefully in the very near future we'll",
        "start": 445.379,
        "duration": 3.151
    },
    {
        "text": "be hearing more about some of our",
        "start": 446.94,
        "duration": 4.65
    },
    {
        "text": "research efforts at sonali but we do",
        "start": 448.53,
        "duration": 5.16
    },
    {
        "text": "feel that the time really is now to be",
        "start": 451.59,
        "duration": 4.859
    },
    {
        "text": "tackling neurodegeneration we borrow",
        "start": 453.69,
        "duration": 4.92
    },
    {
        "text": "from oncology in terms of their success",
        "start": 456.449,
        "duration": 5.37
    },
    {
        "text": "over the past few decades so there was a",
        "start": 458.61,
        "duration": 6.75
    },
    {
        "text": "significant attention to the underlying",
        "start": 461.819,
        "duration": 5.731
    },
    {
        "text": "biology and the oncology field several",
        "start": 465.36,
        "duration": 4.32
    },
    {
        "text": "years ago this led to a lot of oncogene",
        "start": 467.55,
        "duration": 3.69
    },
    {
        "text": "identification terminus oppressors and",
        "start": 469.68,
        "duration": 4.5
    },
    {
        "text": "led to some of the early oncology kinase",
        "start": 471.24,
        "duration": 4.35
    },
    {
        "text": "inhibitors that were approved likely vac",
        "start": 474.18,
        "duration": 3.78
    },
    {
        "text": "there was then an effort to look at",
        "start": 475.59,
        "duration": 5.189
    },
    {
        "text": "personalized healthcare and that led to",
        "start": 477.96,
        "duration": 6.0
    },
    {
        "text": "treatments such as Herceptin which prior",
        "start": 480.779,
        "duration": 4.86
    },
    {
        "text": "to this medication her2 positive breast",
        "start": 483.96,
        "duration": 3.449
    },
    {
        "text": "cancer was saying essentially as a death",
        "start": 485.639,
        "duration": 4.471
    },
    {
        "text": "sentence once her to was then discovered",
        "start": 487.409,
        "duration": 4.591
    },
    {
        "text": "this was now essentially described as",
        "start": 490.11,
        "duration": 3.769
    },
    {
        "text": "some civ ish physicians as a blessing",
        "start": 492.0,
        "duration": 4.319
    },
    {
        "text": "when when you had an unfortunate",
        "start": 493.879,
        "duration": 4.9
    },
    {
        "text": "situation when you had a person with",
        "start": 496.319,
        "duration": 4.71
    },
    {
        "text": "breast cancer and then most recently I",
        "start": 498.779,
        "duration": 4.13
    },
    {
        "text": "think there's hopes for immunotherapy",
        "start": 501.029,
        "duration": 4.651
    },
    {
        "text": "with respect to op debo and Kate ruta a",
        "start": 502.909,
        "duration": 4.54
    },
    {
        "text": "number of other molecules that are",
        "start": 505.68,
        "duration": 5.25
    },
    {
        "text": "advancing for amino oncology and so all",
        "start": 507.449,
        "duration": 6.241
    },
    {
        "text": "of this was really made possible because",
        "start": 510.93,
        "duration": 4.14
    },
    {
        "text": "of the efforts looking at the underlying",
        "start": 513.69,
        "duration": 3.99
    },
    {
        "text": "biology and an attention to",
        "start": 515.07,
        "duration": 4.199
    },
    {
        "text": "translational medicine and so what we're",
        "start": 517.68,
        "duration": 2.849
    },
    {
        "text": "trying to do is really apply this",
        "start": 519.269,
        "duration": 3.63
    },
    {
        "text": "mindset that was successful in oncology",
        "start": 520.529,
        "duration": 5.31
    },
    {
        "text": "to the neurodegeneration field and i",
        "start": 522.899,
        "duration": 4.8
    },
    {
        "text": "don't want to leave with sort of a gloom",
        "start": 525.839,
        "duration": 3.931
    },
    {
        "text": "and doom slide but i wanted to take this",
        "start": 527.699,
        "duration": 3.061
    },
    {
        "text": "as a positive",
        "start": 529.77,
        "duration": 3.18
    },
    {
        "text": "and then talk about what i think is",
        "start": 530.76,
        "duration": 4.2
    },
    {
        "text": "changing in this area and why we feel",
        "start": 532.95,
        "duration": 3.33
    },
    {
        "text": "confident we'll be able to have an",
        "start": 534.96,
        "duration": 4.65
    },
    {
        "text": "impact here and so with respect to the",
        "start": 536.28,
        "duration": 5.04
    },
    {
        "text": "biology and the previous poor",
        "start": 539.61,
        "duration": 3.03
    },
    {
        "text": "understanding i think there's been a lot",
        "start": 541.32,
        "duration": 3.18
    },
    {
        "text": "of advancements there's also been a lot",
        "start": 542.64,
        "duration": 5.34
    },
    {
        "text": "of genetic breakthroughs which we sort",
        "start": 544.5,
        "duration": 4.77
    },
    {
        "text": "of pride ourselves in and using as a",
        "start": 547.98,
        "duration": 3.24
    },
    {
        "text": "hallmark of some of our target selection",
        "start": 549.27,
        "duration": 4.56
    },
    {
        "text": "at Denali there's things through jiwa",
        "start": 551.22,
        "duration": 5.07
    },
    {
        "text": "studies through exome sequencing through",
        "start": 553.83,
        "duration": 4.14
    },
    {
        "text": "familial studies and looking at a number",
        "start": 556.29,
        "duration": 4.02
    },
    {
        "text": "of new genetic insights has also been",
        "start": 557.97,
        "duration": 6.09
    },
    {
        "text": "made possible some sort of clearing of",
        "start": 560.31,
        "duration": 5.07
    },
    {
        "text": "various different pathways through",
        "start": 564.06,
        "duration": 3.18
    },
    {
        "text": "crisper castaign gene editing and so",
        "start": 565.38,
        "duration": 4.2
    },
    {
        "text": "forth the blood-brain barrier is a",
        "start": 567.24,
        "duration": 5.28
    },
    {
        "text": "significant obstacle obstacle I think",
        "start": 569.58,
        "duration": 4.56
    },
    {
        "text": "it's estimated in tons of different",
        "start": 572.52,
        "duration": 4.47
    },
    {
        "text": "reviews that about ninety-eight percent",
        "start": 574.14,
        "duration": 4.83
    },
    {
        "text": "of all small molecules are restricted",
        "start": 576.99,
        "duration": 4.08
    },
    {
        "text": "from the blood from that from the from",
        "start": 578.97,
        "duration": 3.18
    },
    {
        "text": "the brain because of the blood brain",
        "start": 581.07,
        "duration": 2.79
    },
    {
        "text": "barrier and nearly one hundred percent",
        "start": 582.15,
        "duration": 4.44
    },
    {
        "text": "of large molecules or antibodies and so",
        "start": 583.86,
        "duration": 5.13
    },
    {
        "text": "it is a challenge but I think one that I",
        "start": 586.59,
        "duration": 4.98
    },
    {
        "text": "love and that I take on and I think that",
        "start": 588.99,
        "duration": 4.26
    },
    {
        "text": "it's an ollie we're taking on as well",
        "start": 591.57,
        "duration": 4.56
    },
    {
        "text": "and I think some of the focus and",
        "start": 593.25,
        "duration": 4.59
    },
    {
        "text": "attention to things like free drug",
        "start": 596.13,
        "duration": 4.11
    },
    {
        "text": "versus total drug looking at csms",
        "start": 597.84,
        "duration": 3.93
    },
    {
        "text": "surrogate for free free brain",
        "start": 600.24,
        "duration": 4.89
    },
    {
        "text": "concentrations implementing transporter",
        "start": 601.77,
        "duration": 4.86
    },
    {
        "text": "assays early in the drug discovery",
        "start": 605.13,
        "duration": 3.54
    },
    {
        "text": "screening process like MDR assays and so",
        "start": 606.63,
        "duration": 4.89
    },
    {
        "text": "forth is really helping to improve a",
        "start": 608.67,
        "duration": 4.29
    },
    {
        "text": "small molecule drug discovery and then",
        "start": 611.52,
        "duration": 3.66
    },
    {
        "text": "there's also been recent efforts by",
        "start": 612.96,
        "duration": 3.99
    },
    {
        "text": "Genentech and others and looking at",
        "start": 615.18,
        "duration": 4.77
    },
    {
        "text": "large molecule efforts and sort of",
        "start": 616.95,
        "duration": 5.4
    },
    {
        "text": "hijacking transferrin receptors and",
        "start": 619.95,
        "duration": 3.66
    },
    {
        "text": "other things to shuttle things across",
        "start": 622.35,
        "duration": 2.28
    },
    {
        "text": "the blood-brain barrier and that's",
        "start": 623.61,
        "duration": 3.0
    },
    {
        "text": "another area that we're focused on at",
        "start": 624.63,
        "duration": 4.95
    },
    {
        "text": "Denali as well and so the last two here",
        "start": 626.61,
        "duration": 4.77
    },
    {
        "text": "biomarkers and translational medicine",
        "start": 629.58,
        "duration": 4.11
    },
    {
        "text": "I'll just mention as well that I think",
        "start": 631.38,
        "duration": 4.5
    },
    {
        "text": "these are areas that are improving that",
        "start": 633.69,
        "duration": 4.41
    },
    {
        "text": "there's a progress on all of these",
        "start": 635.88,
        "duration": 5.1
    },
    {
        "text": "fronts with respect to biomarkers as",
        "start": 638.1,
        "duration": 5.34
    },
    {
        "text": "Lisa was asking the previous speaker I",
        "start": 640.98,
        "duration": 4.62
    },
    {
        "text": "think there's been breakthroughs with a",
        "start": 643.44,
        "duration": 4.95
    },
    {
        "text": "beta pet imaging there's been CSF",
        "start": 645.6,
        "duration": 5.01
    },
    {
        "text": "biomarkers and looking at a beta and",
        "start": 648.39,
        "duration": 3.84
    },
    {
        "text": "hypo phosphorylated tau and alpha",
        "start": 650.61,
        "duration": 3.93
    },
    {
        "text": "synuclein there's also been",
        "start": 652.23,
        "duration": 4.44
    },
    {
        "text": "breakthroughs with t SPO imaging and",
        "start": 654.54,
        "duration": 3.84
    },
    {
        "text": "looking at neuroinflammation and",
        "start": 656.67,
        "duration": 4.38
    },
    {
        "text": "microglia activation and then with",
        "start": 658.38,
        "duration": 4.77
    },
    {
        "text": "translational medicine as was the case",
        "start": 661.05,
        "duration": 3.24
    },
    {
        "text": "with herceptin i think there",
        "start": 663.15,
        "duration": 4.32
    },
    {
        "text": "been a lot more focus on companion",
        "start": 664.29,
        "duration": 5.82
    },
    {
        "text": "diagnostics and biomarkers in the field",
        "start": 667.47,
        "duration": 6.119
    },
    {
        "text": "and personalized medicine wearable",
        "start": 670.11,
        "duration": 6.659
    },
    {
        "text": "technologies and patient genotyping and",
        "start": 673.589,
        "duration": 4.891
    },
    {
        "text": "so forth that is improving our",
        "start": 676.769,
        "duration": 3.421
    },
    {
        "text": "probability of success so I think it's",
        "start": 678.48,
        "duration": 3.81
    },
    {
        "text": "as you probably heard several times it's",
        "start": 680.19,
        "duration": 3.66
    },
    {
        "text": "about choosing not only the right target",
        "start": 682.29,
        "duration": 3.09
    },
    {
        "text": "and the right molecule but also the",
        "start": 683.85,
        "duration": 3.179
    },
    {
        "text": "right patient population the right dose",
        "start": 685.38,
        "duration": 4.29
    },
    {
        "text": "the right time to intervene and then of",
        "start": 687.029,
        "duration": 4.29
    },
    {
        "text": "course the rat biomarkers to be able to",
        "start": 689.67,
        "duration": 3.659
    },
    {
        "text": "track the activity and ensure that if",
        "start": 691.319,
        "duration": 4.02
    },
    {
        "text": "you do feel that you know why you failed",
        "start": 693.329,
        "duration": 4.351
    },
    {
        "text": "not just that the trial failed and we",
        "start": 695.339,
        "duration": 3.781
    },
    {
        "text": "don't know if it was the molecule or the",
        "start": 697.68,
        "duration": 5.339
    },
    {
        "text": "target that was the the cause so with",
        "start": 699.12,
        "duration": 5.76
    },
    {
        "text": "that I wanted to again thank the",
        "start": 703.019,
        "duration": 4.32
    },
    {
        "text": "organizing committee and Lisa for all of",
        "start": 704.88,
        "duration": 4.5
    },
    {
        "text": "the help and helping with this",
        "start": 707.339,
        "duration": 4.711
    },
    {
        "text": "experience Denali and Genentech which",
        "start": 709.38,
        "duration": 4.49
    },
    {
        "text": "has been amazing places to work",
        "start": 712.05,
        "duration": 4.11
    },
    {
        "text": "specifically Denali over the last year",
        "start": 713.87,
        "duration": 4.06
    },
    {
        "text": "or so has been really fantastic and",
        "start": 716.16,
        "duration": 3.419
    },
    {
        "text": "we're building a great team they're in",
        "start": 717.93,
        "duration": 4.38
    },
    {
        "text": "in south san francisco the entire",
        "start": 719.579,
        "duration": 5.161
    },
    {
        "text": "Genentech lurk to team and then the fox",
        "start": 722.31,
        "duration": 3.99
    },
    {
        "text": "Foundation which have also been great",
        "start": 724.74,
        "duration": 3.12
    },
    {
        "text": "collaborators to work with and Marco",
        "start": 726.3,
        "duration": 3.3
    },
    {
        "text": "specifically who's been leading the",
        "start": 727.86,
        "duration": 3.39
    },
    {
        "text": "alert to efforts so thank you for your",
        "start": 729.6,
        "duration": 3.859
    },
    {
        "text": "time",
        "start": 731.25,
        "duration": 2.209
    }
]